Table 1
Efficacy at week 48, RNA<50 copies/mL | ||||
|---|---|---|---|---|
%, (n/N) | ||||
Initial approach | New analysis | |||
(DRV/r phenotype assumed) | (DRV/r phenotype data) | |||
PSS | RAL | Placebo | RAL | Placebo |
0 | 51 (17/33) | 8 (1/12) | 52 (16/31) | 8 (1/13) |
1 | 48 (34/71) | 13 (7/54) | 45 (34/79) | 15 (8/55) |
2 | 67 (107/160) | 30 (26/88) | 69 (102/148) | 29 (24/83) |
≥3 | 73 (112/153) | 60 (39/65) | 72 (113/156) | 59 (38/64) |